Abstract
Alzheimer’s disease is the most prevalent worldwide neurodegenerative disease (Fargo 2014). It is characterized by a progressive cognitive impairment and behavioral disturbances, which lead to functional impairment (Cummings and Cole 2002).
Keywords
- Nerve Growth Factor
- Cholinergic Neuron
- Amyloid Precursor Protein Processing
- Cholinergic Hypothesis
- Rivastigmine Patch
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alva G, Grossberg GT, Schmitt FA, Meng X, Olin JT (2011) Efficacy of rivastigmine transdermal patch on activities of daily living: Item responder analyses. Int J Geriatr Psychiatry 26(4):356–363
Alvarez A, Alarcón R, Opazo C, Campos EO, Muñoz FJ, Calderón FH et al (1998) Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer’s fibrils. J Neurosci 18(9):3213–3223
Alzheimer’s Association (2015) Alzheimer’s disease facts and figures. Alzheimers Dement 11(3):332–84
Annicchiarico R, Federici A, Pettenati C, Caltagirone C (2007) Rivastigmine in Alzheimer’s disease: cognitive function and quality of life. Ther Clin Risk Manag 3(6):1113–1123
Arciniegas DB (2003) The cholinergic hypothesis of cognitive impairment caused by traumatic brain injury. Curr Psychiatry Rep 5(5):391–399
Arendt T (1999) Pathological anatomy of Alzheimer’s disease (Germ). In: Forstl H, Bickel H, Kurz A (eds) Alzheimer Demenz, Grundlagen Klinik und Therapie. Springer, Berlin/Heidelberg/New York, pp 87–106
Auld DS, Kornecook TJ, Bastianetto S, Quirion R (2002) Alzheimer’s disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 68(3):209–245
Bartus RT, Dean RL, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217(4558):408–414
Battaglia M (2002) Beyond the usual suspects: a cholinergic route for panic attacks. Mol Psychiatry 7(3):239–246
Bentivoglio MS (1990) Brainstem-diencephalic circuits as a structural substrate of ascending reticular activation concept. In: Mancia M, Marini M (eds) The diencephalon and sleep. Raven Press, New York, pp 7–29
Benzi G, Moretti A (1998) Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer’s disease? Eur J Pharmacol 346(1):1–13
Berger-Sweeney J (2003) The cholinergic basal forebrain system during development and its influence on cognitive processes: Important questions and potential answers. Neurosci Biobehav Rev 27(4):401–411
Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP et al (1995) Neurochemical correlates of dementia severity in Alzheimer’s disease: relative importance of the cholinergic deficits. J Neurochem 64(2):749–760
Bigl V, Arendt T, Biesold D (1990) The nucleus basalis of Meynert during aging and in dementing neuropsychiatric disorders. In: Steriade M, Biesold D (eds) Brain cholinergic systems. Oxford University Press, Oxford, pp 364–386
Birks J (2006) Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 1:CD005593
Birks JS, Grimley Evans J (2015) Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 4:CD001191. doi: 10.1002/14651858.CD001191.pub3. Review. PubMed PMID: 25858345
Blesa R, Ballard C, Orgogozo JM, Lane R, Thomas SK (2007) Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology 69(4 Suppl 1):S23–S28
Bornstein RA (1985) Normative data on selected neuropsychological measures from a nonclinical sample. J Clin Psychol 41(5):651–659
Bowen DM, Smith CB, White P, Davison AN (1976) Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99(3):459–496
Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4):239–259
Brankačk J, Platt B, Riedel G (2009) Sleep and hippocampus: do we search for the right things? Prog Neuropsychopharmacol Biol Psychiatry 33(5):806–812
Brun A, Gustafson L (1976) Distribution of cerebral degeneration in Alzheimer’s disease. A clinico-pathological study. Arch Psychiatr Nervenkr 223(1):15–33
Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G et al (2005) Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period. Curr Med Res Opin 21(8):1317–1327
Bürger S, Noack M, Kirazov LP, Kirazov EP, Naydenov CL, Kouznetsova E et al (2009) Vascular endothelial growth factor (VEGF) affects processing of amyloid precursor protein and beta-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain. Int J Dev Neurosci 27(6):517–523
Burghaus L, Schütz U, Krempel U, de Vos RA, Jansen Steur EN, Wevers A et al (2000) Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Res Mol Brain Res 76(2):385–388
Burke SN, Barnes CA (2006) Neural plasticity in the ageing brain. Nat Rev Neurosci 7(1):30–40
Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller HJ et al (1999) The effects of donepezil in Alzheimer’s disease – results from a multinational trial. Dement Geriatr Cogn Disord 10(3):237–244
Caccamo A, Fisher A, LaFerla FM (2009) M1 agonists as a potential disease-modifying therapy for Alzheimer’s disease. Curr Alzheimer Res 6(2):112–117
Cagnin A, Cester A, Costa B, Ermani M, Gabelli C, Gambina G (2014) Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer’s disease. Neurol Sci 36(3):457–463
Chez MG, Aimonovitch M, Buchanan T, Mrazek S, Tremb RJ (2004) Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol 19(3):165–169
Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ et al (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8(1):79–84
Coleman M (2005) Axon degeneration mechanisms: commonality amid diversity. Nat Rev Neurosci 6(11):889–898
Contestabile A (2011) The history of the cholinergic hypothesis. Behav Brain Res 221(2):334–340
Cooke JR, Loredo JS, Liu L, Marler M, Corey-Bloom J, Fiorentino L et al (2006) Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer’s disease. Drugs Aging 23(6):503–511
Cooper JD, Lindholm D, Sofroniew MV (1994) Reduced transport of [125I]nerve growth factor by cholinergic neurons and down-regulated TrkA expression in the medial septum of aged rats. Neuroscience 62(3):625–629
Craig LA, Hong NS, McDonald RJ (2011) Revisiting the cholinergic hypothesis in the development of Alzheimer’s disease. Neurosci Biobehav Rev 35(6):1397–1409
Cuello AC, Bruno MA, Bell KFS (2007) NGF-cholinergic dependency in brain aging, MCI and Alzheimer’s disease. Curr Alzheimer Res 4(4):351–358
Cummings JL, Cole G (2002) Alzheimer disease. JAMA 287:2335–2338
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44(12):2308–2314
Cummings JL, Farlow MR, Meng X, Tekin S, Olin JT (2010a) Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimers disease. Clin Drug Investig 30(1):41–49
Cummings JL, Ferris SH, Farlow MR, Olin JT, Meng X (2010b) Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer’s disease: a retrospective analysis. Dement Geriatr Cogn Disord 29(5):406–412
Cummings J, Froelich L, Black SE, Bakchine S, Bellelli G, Molinuevo JL et al (2012) Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm) in Alzheimer’s disease. Dement Geriatr Cogn Disord 33(5):341–353
Cummings JL, Isaacson RS, Schmitt FA, Velting DM (2015) A practical algorithm for managing Alzheimer’s disease: what, when, and why? Ann Clin Transl Neurol 2(3):307–323
Damasio AR, Graff-Radford NR, Eslinger PJ, Damasio H, Kassell N (1985) Amnesia following basal forebrain lesions. Arch Neurol 42(3):263–271
Darvesh S, Walsh R, Kumar R, Caines A, Roberts S, Magee D et al (2003) Inhibition of human cholinesterases by drugs used to treat Alzheimer disease. Alzheimer Dis Assoc Disord 17(2):117–126
Davies P, Maloney A (1976) Selective loss of central cholinergic neurones in Alzheimer’s disease. Lancet 2:1403
Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M et al (1999) Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 281(15):1401–1406
De Lacalle S, Cooper JD, Svendsen CN, Dunnett SB, Sofroniew MV (1996) Reduced retrograde labelling with fluorescent tracer accompanies neuronal atrophy of basal forebrain cholinergic neurons in aged rats. Neuroscience 75(1):19–27
Decker MW, McGaugh JL (1991) The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 7(2):151–168
DeJong R, Osterlund OW, Roy GW (1989) Measurement of quality-of-life changes in patients with Alzheimer’s disease. Clin Ther 11(4):545–554
DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA et al (2002) Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51(0364–5134):145–155
Deutsch JA (1971) The cholinergic synapse and the site of memory. Science 174(11):788–794
Dhillon S (2011) Rivastigmine transdermal patch. Drugs 71(9):1209–1231
Dickinson-Anson H, Aubert I, Gage FH, Fisher LJ (1998) Hippocampal grafts of acetylcholine-producing cells are sufficient to improve behavioural performance following a unilateral fimbria-fornix lesion. Neuroscience 84(3):771–781
Dilsaver SC, Coffman JA (1989) Cholinergic hypothesis of depression: a reappraisal. J Clin Psychopharmacol 9(3):173–179
Dineley KT, Bell KA, Bui D, Sweatt JD (2002) beta -Amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem 277(28):25056–25061
Doering LC, Snyder EY (2000) Cholinergic expression by a neural stem cell line grafted to the adult medial septum/diagonal band complex. J Neurosci Res 61(6):597–604
Doody RS, Dunn JK, Clark CM, Farlow M, Foster NL, Liao T et al (2001) Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer’s disease. Dement Geriatr Cogn Disord 12(4):295–300
Dournaud P, Deleare P, Hauw JJ, Epelbaum J (1995) Differential correlation between neurochemical deficits, neuropathology, and cognitive status in Alzheimer’s disease. Neurobiol Aging 16(5):817–823
Drachman DA (1977) Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology 27(8):783–790
Drachman DA, Leavitt J (1974) Human memory and the cholinergic system. A relationship to aging? Arch Neurol 30(2):113–121
Drachman DA, Glosser G, Fleming P, Longenecker G (1982) Memory decline in the aged: treatment with lecithin and physostigmine. Neurology 32:944–950
Dziewczapolski G, Glogowski CM, Masliah E, Heinemann SF (2009) Deletion of the α7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer’s disease. J Neurosci 29(27):8805–8815
Efange SMN, Garland EM, Staley JK, Khare AB, Mash DC (1997) Vesicular acetylcholine transporter density and Alzheimer’s disease. Neurobiol Aging 18(4):407–413
Elrod K, Buccafusco JJ (1991) Correlation of the amnestic effects of nicotinic antagonists with inhibition of regional brain acetylcholine synthesis in rats. J Pharmacol Exp Ther 258(2):403–409
Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP et al (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 351(24):2509–2518
Eskander MF, Nagykery NG, Leung EY, Khelghati B, Geula C (2005) Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer’s plaques and tangles. Brain Res 1060(1–2):144–152
Farlow MR, Alva G, Meng X, Olin JT (2010a) A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysis. Curr Med Res Opin 26(2):263–269
Farlow MR, Grossberg G, Gauthier S, Meng X, Olin JT (2010b) The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer’s disease. Curr Med Res Opin 26(10):2441–2447
Fass U, Panickar K, Personett D, Bryan D, Williams K, Gonzales J et al (2000) Differential vulnerability of primary cultured cholinergic neurons to nitric oxide excess. Neuroreport 11(5):931–936
Figiel GS, Sadowsky CH, Strigas J, Koumaras B, Meng X, Gunay I (2008) Safety and efficacy of rivastigmine in patients with Alzheimer’s disease not responding adequately to donepezil: an open-label study. Prim Care Companion J Clin Psychiatry 10(4):291–298
Fodero LR, Mok SS, Losic D, Martin LL, Aguilar MI, Barrow CJ et al (2004) Alpha7-nicotinic acetylcholine receptors mediate an Abeta (1–42)-induced increase in the level of acetylcholinesterase in primary cortical neurones. J Neurochem 88(5):1186–1193
Full prescribing information for Exelon patch: http://www.prnewswire.com/news-releases/novartis-exelon-patch-now-fda-approved-to-treat-patients-across-all-stages-of-alzheimers-disease-213414981.html
Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M et al (1997) An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 11(Suppl 2):S33–S39
Geerts H (2005) Indicators of neuroprotection with galantamine. Brain Res Bull 64(6):519–524
Geula C, Mesulam MM (1996) Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer’s disease. Cereb Cortex 6(2):165–177
Geula C, Mesulam MM (1999) Cholinergic systems in Alzheimer’s disease. In: Terry RD et al (eds) Alzheimer disease, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, pp 69–292
Giacobini E (2001) Do cholinesterase inhibitors have disease-modifying effects in Alzheimer’s disease? CNS Drugs 15(2):85–91
Gibbs RB (2010) Estrogen therapy and cognition: a review of the cholinergic hypothesis. Endocr Rev 31(2):224–253
Gilmor ML, Erickson JD, Varoqui H, Hersh LB, Bennett DA, Cochran EJ, Mufson EJ, Levey A (1999) Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer’s disease. J Comp Neurol 411(4):693–704
Greig NH, Utsuki T, Yu Q, Zhu X, Holloway HW, Perry T et al (2001) A new therapeutic target in Alzheimer’s disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin 17(3):159–165
Grigoryan GA, Gray JA, Rashid T, Chadwick A, Hodges H (2000) Conditionally immortal neuroepithelial stem cell grafts restore spatial learning in rats with lesions at the source of cholinergic forebrain projections cholinergic forebrain projections. Restor Neurol Neurosci 17(4):1
Grossberg GT, Stahelin HB, Messina JC, Anand R, Veach J (2000) Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry 15(3):242–247
Grossberg GT, Sadowsky C, Olin JT (2010a) Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer’s disease. Int J Clin Pract 64(5):651–660
Grossberg GT, Schmitt FA, Meng X, Tekin S, Olin J (2010b) Reviews: effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer’s disease. Am J Alzheimers Dis Other Demen 25(8):627–633
Grossberg G, Meng X, Olin JT (2011) Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer’s disease. Am J Alzheimers Dis Other Demen 26(1):65–71
Grossberg G, Cummings J, Frolich L, Bellelli G, Molinuevo JL, Krahnke T et al (2013) Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer’s disease. Am J Alzheimers Dis Other Demen 28(6):583–591
Gsell W, Jungkunz G, Riederer P (2004) Functional neurochemistry of Alzheimer’s disease. Curr Pharm Des 10(3):265–293
Guillozet al, Smiley JF, Mash DC, Mesulam MM (1997) Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 42(6):909–918
Haring R, Gurwitz D, Barg J, Pinkas-Kramarski R, Heldman E, Pittel Z et al (1995) NGF promotes amyloid precursor protein secretion via muscarinic receptor activation. Biochem Biophys Res Commun 213(1):15–23
Hashimoto R, Mori E (2011) Mini-mental state examination (MMSE). Nihon Rinsho 69 Suppl 8(1975):398–402
Hasselmo ME, Sarter M (2011) Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology 36(1):52–73
Hock C, Maddalena A, Raschig A, Müller-Spahn F, Eschweiler G, Hager K et al (2003) Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of a beta 42 in patients with Alzheimer’s disease. Amyloid 10:1–6
Hornung OP, Regen F, Danker-Hopfe H, Schredl M, Heuser I (2007) The relationship between REM sleep and memory consolidation in old age and effects of cholinergic medication. Biol Psychiatry 61(6):750–757
Hoshi M, Takashima A, Murayama M, Yasutake K, Yoshida N, Ishiguro K et al (1997) Nontoxic amyloid β peptide1-42 suppresses acetylcholine synthesis. Possible role in cholinergic dysfunction in Alzheimer’s disease. J Biol Chem 272(4):2038–2041
Hristensen H, Maltby N, Jorm AF, Creasey H, Broe G (1992) Cholinergic “blockade” as a model of the cognitive deficits in Alzheimer’s disease. Brain 115(Pt 6):1681–1699
Hshieh TT, Fong TG, Marcantonio ER, Inouye SK (2008) Cholinergic deficiency hypothesis in delirium: a synthesis of current evidence. J Gerontol A Biol Sci Med Sci 63(7):764–772
Hunter AJ, Roberts FF (1988) The effect of pirenzepine on spatial learning in the Morris Water Maze. Pharmacol Biochem Behav 30(2):519–523
Isacson O, Seo H, Lin L, Albeck D, Granholm AC (2002) Alzheimer’s disease and Down’s syndrome: roles of APP, trophic factors and ACh. Trends Neurosci 25(2):79–84
Julka D, Sandhir R, Gill KD (1995) Altered cholinergic metabolism in rat CNS following aluminum exposure: implications on learning performance. J Neurochem 65(5):2157–2164
Kar S, Slowikowski SP, Westaway D, Mount HT (2004) Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer’s disease. J Psychiatry Neurosci 29(6):427–441
Kelly JF, Furukawa K, Barger SW, Rengen MR, Mark RJ, Blanc EM et al (1996) Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons. Proc Natl Acad Sci U S A 93(13):6753–6758
Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP et al (1996) In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease. Ann Neurol 40(3):399–410
Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL et al (1999) In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease. Neurology 52(4):691–699
Lane RM, Kivipelto M, Greig NH (2004) Acetylcholinesterase and its inhibition in Alzheimer disease. Clin Neuropharmacol 27(3):141–149
Lee JH, Sevigny J (2011) Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 31(25):58–62
Lefèvre G, Sedek G, Jhee SS et al (2008) Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer’s disease patients. Clin Pharmacol Ther 83(1):106–114
Lefèvre G, Büche M, Sedek G, Maton S, Enz A, Lorch U et al (2009) Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch. J Clin Pharmacol 49:430–443
Lemstra AW, Eikelenboom P, Van Gool WA (2003) The cholinergic deficiency syndrome and its therapeutic implications. Gerontology 49(1):55–60
Levin ED (1992) Nicotinic systems and cognitive function. Psychopharmacology (Berl) 108(4):417–431
Li X, Song L, Jope RS (1996) Cholinergic stimulation of AP-1 and NF kappa B transcription factors is differentially sensitive to oxidative stress in SH-SY5Y neuroblastoma: relationship to phosphoinositide hydrolysis. J Neurosci 16(19):5914–5922
Li Y, Hai S, Zhou Y, Dong BR (2015) Cholinesterase inhibitors for rarer dementias associated with neurological conditions. Cochrane Database Syst Rev 3:CD009444. doi: 10.1002/14651858.CD009444.pub3. Review. PubMed PMID: 25734590
Liskowsky W, Schliebs R (2006) Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer-like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein. Int J Dev Neurosci 24(2-3):149–156
Lleó A (2007) Current therapeutic options for Alzheimer’s disease. Curr Genomics 8(8):550–558
Logsdon RG, Gibbons LE, McCurry SM, Teri L (1999) Quality of life in Alzheimer’s disease: patient and caregiver reports. J Ment Health Aging 5(1):28–36
Luppi PH, Gervasoni D, Verret L, Goutagny R, Peyron C, Salvert D et al (2006) Paradoxical (REM) sleep genesis: The switch from an aminergic-cholinergic to a GABAergic-glutamatergic hypothesis. J Physiol Paris 100(5–6):271–283
Malo M, Diebler MF, Prado De Carvalho L, Meunier FM, Dunant Y, Bloc A et al (1999) Evoked acetylcholine release by immortalized brain endothelial cells genetically modified to express choline acetyltransferase and/or the vesicular acetylcholine transporter. J Neurochem 73(4):1483–1491
McDonald RJ (2002) Multiple combinations of co-factors produce variants of age-related cognitive decline: a theory. Can J Exp Psychol 56(3):221–239
McKinney M (2005) Brain cholinergic vulnerability: relevance to behavior and disease. Biochem Pharmacol 70(8):1115–1124
McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K et al (1999) Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol 46(6):860–866
Medical dictionary for regulatory activities. http://www.meddra.org/
Mega MS, Cummings JL, Salloway S, Malloy P (1997) The limbic system: an anatomic, phylogenetic, and clinical perspective. J Neuropsychiatry Clin Neurosci 9(3):315–330
Mendez MF, Ala T, Underwood KL (1992) Development of scoring criteria for the clock drawing task in Alzheimer’s disease. J Am Geriatr Soc 40(11):1095–1099
Mesulam MM (1995) Structure and function of cholinergic pathways in the cerebral cortex, limbic system basal ganglia and thalamus of the human brain. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology the fourth generation of progress. Raven Press, New York, pp 135–146
Mesulam M (2004) The cholinergic lesion of Alzheimer’s disease: pivotal factor or side show? Learn Mem 11(1):43–49
Mesulam MM, Geula C (1994) Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 36(5):722–727
Mitchell SL, Teno JM, Kiely DK, Shaffer ML, Jones RN, Prigerson HG et al (2009) The clinical course of advanced dementia. N Engl J Med 361(16):1529–1538
Molchan SE, Martinez RA, Hill JL, Weingartner HJ, Thompson KV (1992) B ST. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Rev 17(3):215–226
Molinuevo JL, Frölich L, Grossberg GT, Galvin JE, Cummings JL, Krahnke T et al (2015) Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch. Alzheimers Res Ther 7(1):1–6
Morán MA, Mufson EJ, Gómez-Ramos P (1993) Colocalization of cholinesterases with beta amyloid protein in aged and Alzheimer’s brains. Acta Neuropathol 85(4):362–369
Mori F, Lai CC, Fusi F, Giacobini E (1995) Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuroreport 6(4):633–636
Mufson EJ, Counts SE, Fahnestock M, Ginsberg SD (2007) Cholinotrophic molecular substrates of mild cognitive impairment in the elderly. Curr Alzheimer Res 4(4):340–350
Mufson EJ, Counts SE, Perez SE, Ginsberg SD (2008) Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications. Expert Rev Neurother 8(11):1703–1718
Müller DM, Mendla K, Farber SA, Nitsch RM (1997) Muscarinic m1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain. Life Sci 60(13-14):985–991
Murdoch I, Perry EK, Court JA, Graham DI, Dewar D (1998) Cortical cholinergic dysfunction after human head injury. J Neurotrauma 15(5):295–305
Newhouse PA, Potter A, Corwin J, Lenox R (1994) Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology 10(2):93–107
Newhouse PA, Potter A, Kelton M, Corwin J (2001) Nicotinic treatment of Alzheimer’s disease. Biol Psychiatry 49(3):268–278
Nieoullon A, Bentué-Ferrer D, Bordet R, Tsolaki M, Förstl H (2008) Importance of circadian rhythmicity in the cholinergic treatment of Alzheimer’s disease: focus on galantamine*. Curr Med Res Opin 24(12):3357–3367
Niewiadomska G, Baksalerska-Pazera M, Riedel G (2006) Cytoskeletal transport in the aging brain: focus on the cholinergic system. Rev Neurosci 17(6):581–618
Nilsson L, Nordberg A, Hardy J, Wester P, Winblad B (1986) Physostigmine restores 3H-acetylcholine efflux from Alzheimer brain slices to normal level. J Neural Transm 67(3–4):275–285
Nordberg A (1992) Neuroreceptor changes in Alzheimer disease. Cerebrovasc Brain Metab Rev 4(4):303–328
Nordberg A (2001) Nicotinic receptor abnormalities of Alzheimer’s disease: therapeutic implications. Biol Psychiatry 49(3):200–210
Nordberg A, Alafuzoff I, Winblad B (1992) Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J Neurosci Res 31(1):103–111
Oddo S, Caccamo A, Green KN, Liang K, Tran L, Chen Y et al (2005) Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer’s disease. Proc Natl Acad Sci U S A 102(8):3046–3051
Olin JT, Bhatnagar V, Reyes P, Koumaras B, Meng X, Brannan S (2010) Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer’s disease: A 26-week, open-label, prospective trial (Study ENA713B US32). Int J Geriatr Psychiatry 25(4):419–426
Oz M, Lorke DE, Yang KH, Petroianu G (2013) On the interaction of beta-amyloid peptides and alpha7-nicotinic acetylcholine receptors in Alzheimer’s disease. Curr Alzheimer Res 10(6):618–630
Pedersen WA, Kloczewiak MA, Blusztajn JK (1996) Amyloid beta-protein reduces acetylcholine synthesis in a cell line derived from cholinergic neurons of the basal forebrain. Proc Natl Acad Sci U S A 93(15):8068–8071
Pepeu G, Giovannini MG (2009) Cholinesterase inhibitors and beyond. Curr Alzheimer Res 6(2):86–96
Perini G, Della-Bianca V, Politi V, Della Valle G, Dal-Pra I, Rossi F et al (2002) Role of p75 neurotrophin receptor in the neurotoxicity by beta-amyloid peptides and synergistic effect of inflammatory cytokines. J Exp Med 195(7):907–918
Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE (1977) Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci 34(2):247–265
Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA et al (1985) Cholinergic correlates of cognitive impairment in Parkinson’s disease: comparisons with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 48(5):413–421
Perry E, Tomlinson B, Blessed G, Bergmann K, Gibson P, Perry R (1996) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Int J Geriatr Psychiatry 11(9):765–771
Perry E, Walker M, Grace J, Perry R (1999) Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 22(6):273–280
Picciotto MR, Zoli M (2002) Nicotinic receptors in aging and dementia. J Neurobiol 53(4):641–655
Pinto T, Lanctôt KL, Herrmann N (2011) Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer’s type. Ageing Res Rev 10(4):404–412
Placzek AN, Zhang TA, Dani JA (2009) Nicotinic mechanisms influencing synaptic plasticity in the hippocampus. Acta Pharmacol Sin 30(6):752–760
Racchi M, Sironi M, Caprera A, Konig G, Govoni S (2001) Short- and long-term effect of acetylcholinesterase inhibition on the expression and metabolism of the amyloid precursor protein. Mol Psychiatry 6(5):520–528
Raedler TJ, Bymaster FP, Tandon R, Copolov D, Dean B (2007) Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry 12(3):232–246
Rakonczay Z (2003) Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer’s disease brain. Acta Biol Hung 54(2):183–189
Rapp PR, Gallagher M (1996) Preserved neuron number in the hippocampus of aged rats with spatial learning deficits. Proc Natl Acad Sci U S A 93(18):9926–9930
Rasch BH, Born J, Gais S (2006) Combined blockade of cholinergic receptors shifts the brain from stimulus encoding to memory consolidation. J Cogn Neurosci 18:793–802
Rasmussen T, Schliemann T, SØrensen JC, Zimmer J, West MJ (1996) Memory impaired aged rats: no loss of principal hippocampal and subicular neurons. Neurobiol Aging 17(1):143–147
Reid RT, Sabbagh MN (2008) Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro. J Neural Transm 115(10):1437–1444
Reyes AE, Chacón MA, Dinamarca MC, Cerpa W, Morgan C, Inestrosa NC (2004) Acetylcholinesterase-Abeta complexes are more toxic than Abeta fibrils in rat hippocampus: effect on rat beta-amyloid aggregation, laminin expression, reactive astrocytosis, and neuronal cell loss. Am J Pathol 164(6):2163–2174
Rinne JO, Kaasinen V, Järvenpää T, Någren K, Roivainen A, Yu M et al (2003) Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer’s disease. J Neurol Neurosurg Psychiatry 74(1):113–115
Rivastigmine (Exelon) transdermal patch: risk of medication errors (2010) https://www.gov.uk/drug-safety-update/rivastigmine-exelon-transdermal-patch-risk-of-medication-errors
Roe CM, Xiong C, Miller JP, Morris JC (2007) Education and Alzheimer’s disease without dementia: support for the cognitive reserve hypothesis. Neurology 68:223–228
Rolinski M, Fox C, Maidment I, McShane R (2012) Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease, Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev 3:CD006504
Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry 141(11):1356–1364
Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P et al (1999) Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 318(7184):633–638
Rubio A, Pérez M, Avila J (2006) Acetylcholine receptors and tau phosphorylation. Curr Mol Med 6(4):423–428
Rylett RJ, Ball MJ, Colhoun EH (1983) Evidence for high affinity choline transport in synaptosomes prepared from hippocampus and neocortex of patients with Alzheimer’s disease. Brain Res 289(1–2):169–175
Sadowsky CH, Farlow MR, Atkinson L, Steadman J, Koumaras B, Chen M et al (2005) Switching from donepezil to rivastigmine is well tolerated: results of an open-label safety and tolerability study. Prim Care Companion J Clin Psychiatry 7(2):43–48
Salehi A, Verhaagen J, Dijkhuizen PA, Swaab DF (1996) Co-localization of high-affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer’s disease. Neuroscience 75(2):373–387
Sarter M, Bruno JP (1997) Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Brain Res Rev 23(1–2):28–46
Sarter M, Gehring WJ, Kozak R (2006) More attention must be paid: the neurobiology of attentional effort. Brain Res Rev 51(2):145–160
Sassin I, Schultz C, Thal DR, Rüb U, Arai K, Braak E et al (2000) Evolution of Alzheimer’s disease-related cytoskeletal changes in the basal nucleus of Meynert. Acta Neuropathol 100(3):259–269
Schliebs R (2005) Basal forebrain cholinergic lesion by 192IgG-saporin: a tool to assess the consequences of cortical cholinergic dysfunction in Alzheimer’s disease. In: Wiley RG, Lappi DA (eds) Molecular neurosurgery with targeted toxins. Humana Press, Totowa, pp 59–86
Schliebs R, Arendt T (2006) The significance of the cholinergic system in the brain during aging and in Alzheimer’s disease. J Neural Transm 113(11):1625–1644
Schliebs R, Arendt T (2011) The cholinergic system in aging and neuronal degeneration. Behav Brain Res 221(2):555–563
Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B et al (1997) Validity and reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 11(Suppl 2):S22–S32
Schröder H, Giacobini E, Struble RG, Zilles K, Maelicke A (1991) Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer’s disease. Neurobiol Aging 12(3):259–262
Shearman E, Rossi S, Szasz B, Juranyi Z, Fallon S, Pomara N et al (2006) Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: a microdialysis study. Brain Res Bull 69(2):204–213
Shua-Haim JR, Yap C, Kretov A et al (2008a) Results of next-day crossover study of rivastigmine oral capsules (Exelon) to rivastigmine patch (Exelon Patch) in Alzheimer’s disease patients: a two-month clinical experience [abstract no. P2-411]. Int Conf Alzheimers Dis
Shua-Haim JR, Yap C, Kretov A et al (2008b) Results of next day crossover study of galantamine ER (Razadyne Er) to rivastigmine patch (Exelon patch) in Alzheimer’s disease patients: a two-month clinical experience [abstract no. P2-410]. Int Conf Alzheimers Dis
Shua-Haim J, Yap C, Kretov A et al (2008c) Results of next day crossover study of donepezil (Aricept) to rivastigmine patch (Exelon patch) in Alzheimer’s disease patients: a two month clinical experience [abstract no. P2-407]. Int Conf Alzheimers Dis
Shua-Haim J, Yap C, Kretov A et al (2008d) Results of two-step crossover study of donepezil (Aricept) to rivastigmine patch (Exelon Patch) in Alzheimer’s disease patients: a two-month clinical experience [abstract no. P2-409]. Int Conf Alzheimers Dis
Simic G, Stanic G, Mladinov M, Jovanov-Milosevic N, Kostovic I, Hof PR (2009) Does Alzheimer’s disease begin in the brainstem?: annotation. Neuropathol Appl Neurobiol 35(6):532–554
Small SA, Chawla MK, Buonocore M, Rapp PR, Barnes CA (2004) Imaging correlates of brain function in monkeys and rats isolates a hippocampal subregion differentially vulnerable to aging. Proc Natl Acad Sci U S A 101(18):7181–7186
Smith DE, Roberts J, Gage FH, Tuszynski MH (1999) Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. Proc Natl Acad Sci U S A 96(19):10893–10898
Summary of product characteristics for rivastigmine. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000169/WC500032598.pdf
Szutowicz A, Bielarczyk H, Gul S, Ronowska A, Pawełczyk T, Jankowska-Kulawy A (2006) Phenotype-dependent susceptibility of cholinergic neuroblastoma cells to neurotoxic inputs. Metab Brain Dis 21(2–3):149–161
Tasker A, Perry EK, Ballard CG (2005) Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment. Expert Rev Neurother 5(1):101–106
Terry AV Jr, Buccafusco JJ (2003) The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306(3):821–827
Terry AV, Buccafusco JJ, Jackson WJ (1993) Scopolamine reversal of nicotine enhanced delayed matching-to-sample performance in monkeys. Pharmacol Biochem Behav 45(4):925–929
Tiraboschi P, Hansen LA, Alford M, Masliah E, Thal LJ, Corey-Bloom J (2000) The decline in synapses and cholinergic activity is asynchronous in Alzheimer’s disease. Neurology 55(9):1278–1283
Trillo L, Das D, Hsieh W, Medina B, Moghadam S, Lin B et al (2013) Ascending monoaminergic systems alterations in Alzheimer’s disease. Translating basic science into clinical care. Neurosci Biobehav Rev 37(8):1363–1379
Vagenas V, Vlachos GS, Vlachou N, Liakopoulos D, Kalaitzakis ME, Vikelis M (2015) A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer’s disease treated with rivastigmine transdermal patch. SAGE Open Med. doi: 10.1177/2050312115587795. This open – access article can be found at http://smo.sagepub.com/content/3/2050312115587795.full.pdf+html
Van der Zee EA, Boersma GJ, Hut RA (2009) The neurobiology of circadian rhythms. Curr Opin Pulm Med 15(6):534–539
Van der Zee EA, Platt B, Riedel G (2011) Acetylcholine: future research and perspectives. Behav Brain Res 221(2):583–586
Vitiello B, Martin A, Hill J, Mack C, Molchan S, Martinez R et al (1997) Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans. Neuropsychopharmacology 16(1):15–24
Waller SB, Ball MJ, Reynolds MA, London ED (1986) Muscarinic binding and choline acetyltransferase in postmortem brains of demented patients. Can J Neurol Sci 13(4 Suppl):528–532
Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS et al (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416(6880):535–539
Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B et al (2002) Soluble oligomers of β amyloid (1–42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924(2):133–140
Wang H-Y, Li W, Benedetti NJ, Lee DHS (2003) Alpha 7 nicotinic acetylcholine receptors mediate beta-amyloid peptide-induced tau protein phosphorylation. J Biol Chem 278(34):31547–31553
Weinstock M (1999) Selectivity of cholinesterase inhibition: clinical implications for the treatment of Alzheimer’s disease. CNS Drugs 12(4):307–323
Wenk GL, McGann K, Mencarelli A, Hauss-Wegrzyniak B, Del Soldato P, Fiorucci S (2000) Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic neurons. Eur J Pharmacol 402(1–2):77–85
Wilcock GK, Esiri MM, Bowen DM, Smith CC (1982) Alzheimer’s disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci 57(2–3):407–417
Williams B, Granholm AC, Sambamurti K (2007) Age-dependent loss of NGF signaling in the rat basal forebrain is due to disrupted MAPK activation. Neurosci Lett 413(2):110–114
Winblad B, Grossberg G, Frölich L, Farlow M, Zechner S, Nagel J et al (2007) IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 69(4 Suppl 1):S14–S22
Ypsilanti AR, Girão da Cruz MT, Burgess A, Aubert I (2008) The length of hippocampal cholinergic fibers is reduced in the aging brain. Neurobiol Aging 29(11):1666–1679
Zubieta JK, Koeppe RA, Frey KA, Kilbourn MR, Mangner TJ, Foster NL et al (2001) Assessment of muscarinic receptor concentrations in aging and Alzheimer disease with [11C]NMPB and PET. Synapse 39(4):275–287
Acknowledgments
Dr. Ignacio Flores, co-author, Memory Unit, Neurology Service, Hospital de la Santa Creu i Sant Pau – Autonomous University of Barcelona, Spain and Hospital San Martin de La Plata, Buenos Aires, Argentina.
Dr. Roser Ribosa, co-author, Memory Unit, Neurology Service, Hospital de la Santa Creu i Sant Pau – Autonomous University of Barcelona, Spain.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Gonzalez, R.B., Flores, I., Ribosa-Nogué, R. (2016). Practical Pharmacology of Rivastigmine. In: Practical Pharmacology for Alzheimer’s Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-26206-2_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-26206-2_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-26204-8
Online ISBN: 978-3-319-26206-2
eBook Packages: MedicineMedicine (R0)